Ipca Laboratories Limited (IPCALAB.BO)
INR 1573.8
(3.81%)
INR 1573.8
(3.81%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 29.8 Billion INR | -19.36% |
| 2022 | 37.99 Billion INR | 3.79% |
| 2021 | 36.6 Billion INR | 2.7% |
| 2020 | 35.64 Billion INR | 25.07% |
| 2019 | 28.49 Billion INR | 18.65% |
| 2018 | 24.01 Billion INR | 18.29% |
| 2017 | 20.3 Billion INR | 5.24% |
| 2016 | 19.29 Billion INR | 9.78% |
| 2015 | 17.57 Billion INR | -7.83% |
| 2014 | 19.06 Billion INR | -7.53% |
| 2013 | 20.62 Billion INR | 26.1% |
| 2012 | 16.35 Billion INR | 18.79% |
| 2011 | 13.76 Billion INR | 22.54% |
| 2010 | 11.23 Billion INR | 22.91% |
| 2009 | 9.13 Billion INR | 17.7% |
| 2008 | 7.76 Billion INR | 32.19% |
| 2007 | 5.87 Billion INR | 11.47% |
| 2006 | 5.26 Billion INR | 28.5% |
| 2005 | 4.1 Billion INR | 100.37% |
| 2004 | 2.04 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 8.62 Billion INR | 10.14% |
| 2023 Q2 | 13.56 Billion INR | 26.5% |
| 2023 Q1 | 10.72 Billion INR | 37.12% |
| 2023 FY | 30.63 Billion INR | -19.36% |
| 2023 Q3 | 13.55 Billion INR | -0.03% |
| 2023 Q4 | 7.82 Billion INR | -42.25% |
| 2022 Q1 | 10.07 Billion INR | 42.14% |
| 2022 Q3 | 9.84 Billion INR | -4.09% |
| 2022 Q4 | 7.81 Billion INR | -20.54% |
| 2022 Q2 | 10.26 Billion INR | 1.9% |
| 2022 FY | 37.99 Billion INR | 3.79% |
| 2021 FY | 36.6 Billion INR | 2.7% |
| 2021 Q2 | 10 Billion INR | -1.97% |
| 2021 Q3 | 9.31 Billion INR | -6.81% |
| 2021 Q4 | 7.08 Billion INR | -23.98% |
| 2021 Q1 | 10.2 Billion INR | 63.59% |
| 2020 FY | 35.64 Billion INR | 25.07% |
| 2020 Q4 | 6.23 Billion INR | -30.28% |
| 2020 Q3 | 8.94 Billion INR | -2.61% |
| 2020 Q2 | 9.18 Billion INR | -16.72% |
| 2020 Q1 | 11.02 Billion INR | 98.89% |
| 2019 FY | 28.49 Billion INR | 18.65% |
| 2019 Q3 | 7.89 Billion INR | -5.41% |
| 2019 Q4 | 5.54 Billion INR | -29.73% |
| 2019 Q1 | 6.72 Billion INR | 52.33% |
| 2019 Q2 | 8.34 Billion INR | 24.1% |
| 2018 Q2 | 6.99 Billion INR | 17.74% |
| 2018 FY | 24.01 Billion INR | 18.29% |
| 2018 Q4 | 4.41 Billion INR | -33.87% |
| 2018 Q3 | 6.67 Billion INR | -4.58% |
| 2018 Q1 | 5.93 Billion INR | 0.0% |
| 2017 FY | 20.3 Billion INR | 5.24% |
| 2016 FY | 19.29 Billion INR | 9.78% |
| 2015 FY | 17.57 Billion INR | -7.83% |
| 2014 FY | 19.06 Billion INR | -7.53% |
| 2013 FY | 20.62 Billion INR | 26.1% |
| 2012 FY | 16.35 Billion INR | 18.79% |
| 2011 FY | 13.76 Billion INR | 22.54% |
| 2010 FY | 11.23 Billion INR | 22.91% |
| 2009 FY | 9.13 Billion INR | 17.7% |
| 2008 FY | 7.76 Billion INR | 32.19% |
| 2007 FY | 5.87 Billion INR | 11.47% |
| 2006 FY | 5.26 Billion INR | 28.5% |
| 2005 FY | 4.1 Billion INR | 100.37% |
| 2004 FY | 2.04 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | -41.521% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -1815.149% |
| Sigachi Industries Limited | 2 Billion INR | -1388.796% |
| Bal Pharma Limited | 770.19 Million INR | -3770.435% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | -381.243% |
| Medico Remedies Limited | 262.14 Million INR | -11271.574% |
| Lasa Supergenerics Limited | 121.02 Million INR | -24530.175% |
| Venus Remedies Limited | 2.18 Billion INR | -1265.807% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 5048.473% |
| Alpa Laboratories Limited | 188.89 Million INR | -15681.201% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -903.005% |
| Shilpa Medicare Limited | 3.54 Billion INR | -740.459% |
| Aarti Drugs Limited | 8.31 Billion INR | -258.456% |
| Lupin Limited | 123.71 Billion INR | 75.905% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 80.728% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 76.192% |
| Windlas Biotech Limited | 1.33 Billion INR | -2126.613% |
| Suven Life Sciences Limited | -200.79 Million INR | 14945.79% |
| Eris Lifesciences Limited | 10.42 Billion INR | -185.897% |
| Valiant Laboratories Limited | -60.66 Million INR | 49239.358% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | -31.322% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -3361.438% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -706.668% |
| Achyut Healthcare Limited | 4.86 Million INR | -613146.246% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 88.467% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -1925.396% |
| RPG Life Sciences Limited | 2.48 Billion INR | -1100.56% |
| Mankind Pharma Limited | 44.52 Billion INR | 33.043% |
| Laurus Labs Limited | 24.62 Billion INR | -21.08% |
| Piramal Pharma Limited | 24.47 Billion INR | -21.818% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -3063.193% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 36.245% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | -11.311% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 57.009% |
| Unichem Laboratories Limited | 4.86 Billion INR | -512.751% |
| Sequent Scientific Limited | 2.97 Billion INR | -900.759% |
| Novartis India Limited | 1.32 Billion INR | -2146.582% |
| Wanbury Limited | 1.73 Billion INR | -1622.475% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -622.967% |
| Wockhardt Limited | 16.24 Billion INR | -83.558% |
| Themis Medicare Limited | 1.5 Billion INR | -1882.168% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -4467.937% |
| Jubilant Pharmova Limited | 19.64 Billion INR | -51.758% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | -139.765% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 81.78% |
| Divi's Laboratories Limited | 32.44 Billion INR | 8.108% |
| NATCO Pharma Limited | 25.73 Billion INR | -15.83% |
| Gufic Biosciences Limited | 4.16 Billion INR | -615.259% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -550.758% |
| Ind-Swift Limited | 2.17 Billion INR | -1272.128% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -415.617% |
| FDC Limited | 8.33 Billion INR | -257.658% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -15367.423% |
| Granules India Limited | 16.79 Billion INR | -77.447% |
| Medicamen Biotech Limited | 495.49 Million INR | -5916.186% |
| Alkem Laboratories Limited | 52.29 Billion INR | 42.999% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -379.051% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -204361.683% |
| Brooks Laboratories Limited | 65.62 Million INR | -45328.071% |
| Megasoft Limited | 342.07 Million INR | -8614.536% |
| ZIM Laboratories Limited | 1.26 Billion INR | -2253.004% |
| Strides Pharma Science Limited | 14.38 Billion INR | -107.184% |
| Neuland Laboratories Limited | 8.24 Billion INR | -261.427% |
| Morepen Laboratories Limited | 6.16 Billion INR | -383.826% |
| Hikal Limited | 3.14 Billion INR | -848.43% |
| Indoco Remedies Limited | 6.04 Billion INR | -393.433% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -411.2% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -4704.352% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -4136.738% |
| Hester Biosciences Limited | 1.27 Billion INR | -2240.51% |